Remember meForgot password?
    Log in with Twitter
Press Release

Globalization of Clinical Studies and Stringent Regulations Spur Adoption of E-Clinical Trial Technologies, According to New Report by Global Industry Analysts, Inc.

>PRWEB.COM Newswire

San Jose, California (PRWEB) April 08, 2013

Follow us on LinkedIn – Biotechnology and pharmaceutical companies and CROs are under continuous pressure to reduce the time lag between conclusion of the clinical study and submission to the concerned regulatory authorities for approval. Increasing internationalization and outsourcing of drug development processes and the growing complexity of Phase IV or post-marketing studies, are providing opportunities for management solutions like e-Clinical technologies that help minimize costs. Key factors influencing the market include increasing pressure on pharma companies to enhance productivity of and control over processes involved in drug development and stringent drug development and approval regulations. Growth is largely dependent on the health and competiveness of the pharmaceutical industry. A key determinant of growth is the number of new drug development programs and clinical trials conducted.

Clinical study sponsors and operators across the world are adopting e-clinical trial technologies like CTMS, EDC, ePROs, RTSM, IVRS and IWRS, given the ability of these technologies to transform the way clinical trials are conducted. The widespread use of traditional and outdated systems for capturing and storing data provides huge untapped potential for growth. Adoption of e-Clinical trial technologies is additionally fueled by the acceptance of electronic submissions of clinical data by regulatory authorities, especially the USFDA, and organizations like CDISC. This is accelerating the fundamental shift of clinical studies from paper-based processes and infrastructure to electronic format and solutions.

Clinical study operators are gradually migrating from individual technologies to integrated solutions that combine disparate systems to reduce data redundancy and improve workflow efficiency. Cloud computing or Software-as-a-Service is rapidly growing in popularity as a preferred model for delivery of clinical trial solutions. Cost advantages, flexibility and functionality are key benefits driving customer acceptance of cloud solutions. Open source technologies are emerging into a preferred platform given its cost advantages and interoperability benefits over proprietary platforms.

Electronic Data Capture (EDC) represents the largest technology sector in the global e-Clinical trial technologies market. EDC systems are rapidly emerging as de-facto tools in clinical studies, replacing traditional paper based systems. There is a growing need for integration of EDC with ePRO and other non e-Clinical technologies to improve the effectiveness and efficiency of clinical trials management.

Clinical Trial Management Systems (CTMS) represents the fastest growing technology segment. CTMS is rapidly emerging as a key solution for drug developers to achieve process efficiencies with post-marketing studies, where automation and sampling remain key issues. Web-based CTMS solutions are the largest revenue generators in the global CTMS market.

Smartphones, tablets and dedicated handheld devices are gaining in popularity among ePRO system users due to advantages such as speedy feedback, and anytime, anywhere access to trial data. Mobile technology is widely being used in various clinical research processes, particularly in electronic patient reported outcome (ePRO), guided by benefits like improved data management, increased efficiencies, enhanced security and ease of service delivery.

As stated by the new market research report on E-Clinical Trial Technologies, the United States represents the largest market worldwide. With cost pressures driving the exodus of clinical trials to developing countries in Asia-Pacific and Latin America, these markets are forecast to emerge as the fastest growing markets worldwide. Asia-pacific is expected to grow at a projected CAGR of 17% over the analysis period.

Major players profiled in the report include ArisGlobal LLC, BioClinica Inc., Clinipace Worldwide, Cmed Technology Ltd., DATATRAK International Inc., DSG Inc., eClinForce Inc., DZS Software Solutions Inc., eResearch Technology Inc., Medidata Solutions Inc., Integrated Clinical Solutions Inc., Merge Healthcare Inc., MedNet Solutions, Nextrials Inc., Oracle Health Sciences, Perceptive Informatics Inc., PharmaPros Corporation, and SAS Institute Inc., among others.

The research report titled “E-Clinical Trial Technologies: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues, drivers, company profiles, mergers, acquisitions and other strategic industry activities. The report provides market estimates and projections in US$ for all major geographic markets including the United States, Canada, Europe, Asia-Pacific, and Rest of World. Key E-Clinical Trial Technologies analyzed include Electronic Data Capture (EDC), Clinical Trial Management System (CTMS), Electronic Patient Reported Outcome (ePROs), RTSM (Randomization and Trial Supply Management) Systems, and IRT (Interactive Response Technology). The EDC and CTMS segments are further analyzed by Clinical Trial Phase and Delivery Mode.

For more details about this comprehensive market research report, please visit –

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site:


Read the full story at

Latest News
Top News